Build Your Comparison

Side-by-side financial analysis
NAKA logo
NAKA
UNH logo
UNH
KO logo
KO
CVS logo
CVS
TDOC logo
TDOC
JPM logo
JPM
Try popular comparisons:

Stock Comparison

NAKA vs UNH vs KO vs CVS vs TDOC vs JPM

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
NAKA
Nakamoto Inc.

Financial - Capital Markets

Financial ServicesNASDAQ • US
Market Cap$79M
5Y Perf.-96.3%
UNH
UnitedHealth Group Incorporated

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$373.09B
5Y Perf.-17.0%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$348.25B
5Y Perf.+28.6%
CVS
CVS Health Corporation

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$128.46B
5Y Perf.+68.9%
TDOC
Teladoc Health, Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$1.35B
5Y Perf.-33.6%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$892.31B
5Y Perf.+57.6%

NAKA vs UNH vs KO vs CVS vs TDOC vs JPM — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
NAKA logoNAKA
UNH logoUNH
KO logoKO
CVS logoCVS
TDOC logoTDOC
JPM logoJPM
IndustryFinancial - Capital MarketsMedical - Healthcare PlansBeverages - Non-AlcoholicMedical - Healthcare PlansMedical - Healthcare Information ServicesBanks - Diversified
Market Cap$79M$373.09B$348.25B$128.46B$1.35B$892.31B
Revenue (TTM)$4M$449.71B$49.28B$407.90B$2.51B$280.33B
Net Income (TTM)$-290M$12.04B$13.70B$2.93B$-171M$57.05B
Gross Margin-376.0%18.8%61.7%13.9%65.6%60.0%
Operating Margin-82.2%4.2%29.3%1.5%-7.6%25.9%
Forward P/E22.4x24.7x13.6x14.3x
Total Debt$210M$78.39B$45.49B$93.59B$1.04B$942.38B
Cash & Equiv.$23M$24.36B$10.27B$8.51B$781M$343.34B

NAKA vs UNH vs KO vs CVS vs TDOC vs JPMLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

NAKA
UNH
KO
CVS
TDOC
JPM
StockMay 24Jun 26Return
Nakamoto Inc. (NAKA)1003.7-96.3%
UnitedHealth Group … (UNH)10083.0-17.0%
The Coca-Cola Compa… (KO)100128.6+28.6%
CVS Health Corporat… (CVS)100168.9+68.9%
Teladoc Health, Inc. (TDOC)10066.4-33.6%
JPMorgan Chase & Co. (JPM)100157.6+57.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: NAKA vs UNH vs KO vs CVS vs TDOC vs JPM

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CVS leads in 4 of 7 categories (6-stock set), making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. The Coca-Cola Company is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. UNH also leads in specific categories worth noting. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
🥇CVS emerged as the overall leader. Track its performance:
NAKA
Nakamoto Inc.
The Financial Services Pick

NAKA lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: financial services exposure
UNH
UnitedHealth Group Incorporated
The Insurance Pick

UNH ranks third and is worth considering specifically for growth exposure.

  • Rev growth 11.8%, EPS growth -14.7%, 3Y rev CAGR 11.4%
  • 11.8% revenue growth vs NAKA's -33.0%
Best for: growth exposure
KO
The Coca-Cola Company
The Quality Compounder

KO is the #2 pick in this set and the best alternative if quality and efficiency is your priority.

  • 27.8% margin vs NAKA's -74.0%
  • 13.1% ROA vs NAKA's -56.5%, ROIC 15.8% vs -42.1%
Best for: quality and efficiency
CVS
CVS Health Corporation
The Insurance Pick

CVS carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.

  • Dividend streak 0 yrs, beta 0.19, yield 2.7%
  • Lower volatility, beta 0.19, current ratio 0.84x
  • Beta 0.19, yield 2.7%, current ratio 0.84x
  • Lower P/E (13.6x vs 24.7x)
Best for: income & stability and sleep-well-at-night
TDOC
Teladoc Health, Inc.
The Healthcare Pick

Among these 6 stocks, TDOC doesn't own a clear edge in any measured category.

Best for: healthcare exposure
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM is the clearest fit if your priority is long-term compounding and valuation efficiency.

  • 475.6% 10Y total return vs KO's 118.2%
  • PEG 0.81 vs KO's 2.21
Best for: long-term compounding and valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthUNH logoUNH11.8% revenue growth vs NAKA's -33.0%
ValueCVS logoCVSLower P/E (13.6x vs 24.7x)
Quality / MarginsKO logoKO27.8% margin vs NAKA's -74.0%
Stability / SafetyCVS logoCVSBeta 0.19 vs NAKA's 2.88
DividendsCVS logoCVS2.7% yield, vs KO's 2.5%, (2 stocks pay no dividend)
Momentum (1Y)CVS logoCVS+52.6% vs NAKA's -99.3%
Efficiency (ROA)KO logoKO13.1% ROA vs NAKA's -56.5%, ROIC 15.8% vs -42.1%

NAKA vs UNH vs KO vs CVS vs TDOC vs JPM — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
NAKANakamoto Inc.
FY 2025
Product Retail Sales
100.0%$1,479
UNHUnitedHealth Group Incorporated
FY 2025
Unitedhealthcare
94.4%$332.4B
Optumhealth
5.6%$19.8B
KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B
CVSCVS Health Corporation
FY 2025
Pharmacy Revenue
58.9%$229.0B
Premiums
34.6%$134.8B
Front Store Revenue
5.5%$21.5B
Product and Service, Other
1.0%$3.9B
TDOCTeladoc Health, Inc.
FY 2025
Other
100.0%$438M
JPMJPMorgan Chase & Co.
FY 2025
Commercial And Investment Bank
43.0%$78.5B
Consumer & Community Banking
41.7%$76.0B
Asset and Wealth Management Segment
13.2%$24.1B
Segment Reporting, Reconciling Item, Corporate Nonsegment
3.9%$7.0B
Segment Reconciling Items
-1.7%$-3,134,000,000

NAKA vs UNH vs KO vs CVS vs TDOC vs JPM — Financial Metrics

Side-by-side numbers across 6 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLKOLAGGINGTDOC

Income & Cash Flow (Last 12 Months)

KO leads this category, winning 2 of 6 comparable metrics.

UNH is the larger business by revenue, generating $449.7B annually — 114732.7x NAKA's $4M. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to NAKA's -74.0%. On growth, NAKA holds the edge at +3.6% YoY revenue growth, suggesting stronger near-term business momentum.

MetricNAKA logoNAKANakamoto Inc.UNH logoUNHUnitedHealth Grou…KO logoKOThe Coca-Cola Com…CVS logoCVSCVS Health Corpor…TDOC logoTDOCTeladoc Health, I…JPM logoJPMJPMorgan Chase & …
RevenueTrailing 12 months$4M$449.7B$49.3B$407.9B$2.5B$280.3B
EBITDAEarnings before interest/tax-$320M$23.2B$15.5B$10.5B$42M$81.4B
Net IncomeAfter-tax profit-$290M$12.0B$13.7B$2.9B-$171M$57.0B
Free Cash FlowCash after capex-$46M$19.7B$12.6B$7.4B$251M$100.9B
Gross MarginGross profit ÷ Revenue-3.8%+18.8%+61.7%+13.9%+65.6%+60.0%
Operating MarginEBIT ÷ Revenue-82.2%+4.2%+29.3%+1.5%-7.6%+25.9%
Net MarginNet income ÷ Revenue-74.0%+2.7%+27.8%+0.7%-6.8%+20.4%
FCF MarginFCF ÷ Revenue-11.7%+4.4%+25.5%+1.8%+10.0%+36.0%
Rev. Growth (YoY)Latest quarter vs prior year+3.6%+2.0%+12.1%+6.2%-2.5%
EPS Growth (YoY)Latest quarter vs prior year-88.4%+0.7%+18.2%+63.1%+32.1%+16.0%
KO leads this category, winning 2 of 6 comparable metrics.

Valuation Metrics

CVS leads this category, winning 3 of 7 comparable metrics.

At 15.9x trailing earnings, JPM trades at a 78% valuation discount to CVS's 72.4x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.90x vs KO's 2.38x — a lower PEG means you pay less per unit of expected earnings growth.

MetricNAKA logoNAKANakamoto Inc.UNH logoUNHUnitedHealth Grou…KO logoKOThe Coca-Cola Com…CVS logoCVSCVS Health Corpor…TDOC logoTDOCTeladoc Health, I…JPM logoJPMJPMorgan Chase & …
Market CapShares × price$79M$373.1B$348.2B$128.5B$1.3B$892.3B
Enterprise ValueMkt cap + debt − cash$266M$427.1B$383.5B$213.5B$1.6B$1.49T
Trailing P/EPrice ÷ TTM EPS-0.43x31.07x26.62x72.43x-6.54x15.93x
Forward P/EPrice ÷ next-FY EPS est.22.35x24.75x13.61x14.34x
PEG RatioP/E ÷ EPS growth rate2.38x0.90x
EV / EBITDAEnterprise value multiple18.31x25.89x14.24x16.02x18.32x
Price / SalesMarket cap ÷ Revenue43.19x0.83x7.26x0.32x0.53x3.19x
Price / BookPrice ÷ Book value/share0.10x3.68x10.18x1.70x0.95x2.46x
Price / FCFMarket cap ÷ FCF23.21x65.76x16.45x4.72x8.85x
CVS leads this category, winning 3 of 7 comparable metrics.

Profitability & Efficiency

KO leads this category, winning 6 of 9 comparable metrics.

KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-85 for NAKA. NAKA carries lower financial leverage with a 0.41x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), KO scores 7/9 vs NAKA's 2/9, reflecting strong financial health.

MetricNAKA logoNAKANakamoto Inc.UNH logoUNHUnitedHealth Grou…KO logoKOThe Coca-Cola Com…CVS logoCVSCVS Health Corpor…TDOC logoTDOCTeladoc Health, I…JPM logoJPMJPMorgan Chase & …
ROE (TTM)Return on equity-84.8%+11.5%+41.1%+3.9%-12.4%+15.9%
ROA (TTM)Return on assets-56.5%+3.9%+13.1%+1.1%-5.9%+1.3%
ROICReturn on invested capital-42.1%+9.2%+15.8%+5.0%-11.5%+4.5%
ROCEReturn on capital employed-76.2%+9.7%+17.3%+6.1%-10.0%+8.9%
Piotroski ScoreFundamental quality 0–9267565
Debt / EquityFinancial leverage0.41x0.77x1.33x1.24x0.75x2.60x
Net DebtTotal debt minus cash$187M$54.0B$35.2B$85.1B$259M$599.0B
Cash & Equiv.Liquid assets$23M$24.4B$10.3B$8.5B$781M$343.3B
Total DebtShort + long-term debt$210M$78.4B$45.5B$93.6B$1.0B$942.4B
Interest CoverageEBIT ÷ Interest expense-24.72x4.71x10.70x2.11x-8.76x0.74x
KO leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

JPM leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in JPM five years ago would be worth $22,071 today (with dividends reinvested), compared to $374 for NAKA. Over the past 12 months, CVS leads with a +52.6% total return vs NAKA's -99.3%. The 3-year compound annual growth rate (CAGR) favors JPM at 32.7% vs NAKA's -66.6% — a key indicator of consistent wealth creation.

MetricNAKA logoNAKANakamoto Inc.UNH logoUNHUnitedHealth Grou…KO logoKOThe Coca-Cola Com…CVS logoCVSCVS Health Corpor…TDOC logoTDOCTeladoc Health, I…JPM logoJPMJPMorgan Chase & …
YTD ReturnYear-to-date-72.3%+23.5%+18.6%+27.3%+5.8%-0.9%
1-Year ReturnPast 12 months-99.3%+37.2%+17.7%+52.6%+6.3%+20.3%
3-Year ReturnCumulative with dividends-96.3%-6.0%+42.6%+56.2%-70.4%+133.8%
5-Year ReturnCumulative with dividends-96.3%+12.6%+63.1%+32.3%-95.1%+120.7%
10-Year ReturnCumulative with dividends-96.3%+241.6%+118.2%+27.9%-42.8%+475.6%
CAGR (3Y)Annualised 3-year return-66.6%-2.0%+12.6%+16.0%-33.4%+32.7%
JPM leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — UNH and KO each lead in 1 of 2 comparable metrics.

KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than NAKA's 2.88 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. UNH currently trades 98.8% from its 52-week high vs NAKA's 0.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricNAKA logoNAKANakamoto Inc.UNH logoUNHUnitedHealth Grou…KO logoKOThe Coca-Cola Com…CVS logoCVSCVS Health Corpor…TDOC logoTDOCTeladoc Health, I…JPM logoJPMJPMorgan Chase & …
Beta (5Y)Sensitivity to S&P 5002.88x0.61x-0.20x0.19x1.85x0.94x
52-Week HighHighest price in past year$679.20$415.96$84.04$102.77$9.77$337.25
52-Week LowLowest price in past year$0.38$234.60$65.35$58.50$4.40$266.85
% of 52W HighCurrent price vs 52-week peak+0.7%+98.8%+96.3%+98.0%+76.4%+94.7%
RSI (14)Momentum oscillator 0–10035.467.960.874.759.065.0
Avg Volume (50D)Average daily shares traded274K7.2M12.7M7.5M4.4M7.0M
Evenly matched — UNH and KO each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — KO and CVS each lead in 1 of 2 comparable metrics.

Analyst consensus: NAKA as "Buy", UNH as "Buy", KO as "Buy", CVS as "Buy", TDOC as "Hold", JPM as "Buy". Consensus price targets imply 77.0% upside for NAKA (target: $8) vs -0.8% for TDOC (target: $7). For income investors, CVS offers the higher dividend yield at 2.65% vs JPM's 1.86%.

MetricNAKA logoNAKANakamoto Inc.UNH logoUNHUnitedHealth Grou…KO logoKOThe Coca-Cola Com…CVS logoCVSCVS Health Corpor…TDOC logoTDOCTeladoc Health, I…JPM logoJPMJPMorgan Chase & …
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyHoldBuy
Price TargetConsensus 12-month target$8.00$418.50$86.13$103.64$7.40$339.75
# AnalystsCovering analysts25248414261
Dividend YieldAnnual dividend ÷ price+2.1%+2.5%+2.7%+1.9%
Dividend StreakConsecutive years of raises01656015
Dividend / ShareAnnual DPS$8.70$2.04$2.67$5.95
Buyback YieldShare repurchases ÷ mkt cap+0.4%+1.5%+0.2%0.0%0.0%+3.9%
Evenly matched — KO and CVS each lead in 1 of 2 comparable metrics.
Key Takeaway

KO leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CVS leads in 1 (Valuation Metrics). 2 tied.

Best OverallThe Coca-Cola Company (KO)Leads 2 of 6 categories
Loading custom metrics...

NAKA vs UNH vs KO vs CVS vs TDOC vs JPM: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is NAKA or UNH or KO or CVS or TDOC or JPM a better buy right now?

For growth investors, UnitedHealth Group Incorporated (UNH) is the stronger pick with 11.

8% revenue growth year-over-year, versus -33. 0% for Nakamoto Inc. (NAKA). JPMorgan Chase & Co. (JPM) offers the better valuation at 15. 9x trailing P/E (14. 3x forward), making it the more compelling value choice. Analysts rate Nakamoto Inc. (NAKA) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — NAKA or UNH or KO or CVS or TDOC or JPM?

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 15. 9x versus CVS Health Corporation at 72. 4x. On forward P/E, CVS Health Corporation is actually cheaper at 13. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus The Coca-Cola Company's 2. 21x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — NAKA or UNH or KO or CVS or TDOC or JPM?

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +120. 7%, compared to -96. 3% for Nakamoto Inc. (NAKA). Over 10 years, the gap is even starker: JPM returned +475. 6% versus NAKA's -96. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — NAKA or UNH or KO or CVS or TDOC or JPM?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Nakamoto Inc. 's 2. 88β — meaning NAKA is approximately -1540% more volatile than KO relative to the S&P 500. On balance sheet safety, Nakamoto Inc. (NAKA) carries a lower debt/equity ratio of 41% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

05

Which is growing faster — NAKA or UNH or KO or CVS or TDOC or JPM?

By revenue growth (latest reported year), UnitedHealth Group Incorporated (UNH) is pulling ahead at 11.

8% versus -33. 0% for Nakamoto Inc. (NAKA). On earnings-per-share growth, the picture is similar: Teladoc Health, Inc. grew EPS 80. 6% year-over-year, compared to -1452. 2% for Nakamoto Inc.. Over a 3-year CAGR, UNH leads at 11. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — NAKA or UNH or KO or CVS or TDOC or JPM?

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -28. 7% for Nakamoto Inc. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -108. 2% for NAKA. At the gross margin level — before operating expenses — TDOC leads at 69. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is NAKA or UNH or KO or CVS or TDOC or JPM more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus The Coca-Cola Company's 2. 21x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, CVS Health Corporation (CVS) trades at 13. 6x forward P/E versus 24. 7x for The Coca-Cola Company — 11. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NAKA: 77. 0% to $8. 00.

08

Which pays a better dividend — NAKA or UNH or KO or CVS or TDOC or JPM?

In this comparison, CVS (2.

7% yield), KO (2. 5% yield), UNH (2. 1% yield), JPM (1. 9% yield) pay a dividend. NAKA, TDOC do not pay a meaningful dividend and should not be held primarily for income.

09

Is NAKA or UNH or KO or CVS or TDOC or JPM better for a retirement portfolio?

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +118. 2% 10Y return). Nakamoto Inc. (NAKA) carries a higher beta of 2. 88 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +118. 2%, NAKA: -96. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between NAKA and UNH and KO and CVS and TDOC and JPM?

These companies operate in different sectors (NAKA (Financial Services) and UNH (Healthcare) and KO (Consumer Defensive) and CVS (Healthcare) and TDOC (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NAKA is a small-cap quality compounder stock; UNH is a large-cap quality compounder stock; KO is a large-cap quality compounder stock; CVS is a mid-cap quality compounder stock; TDOC is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. UNH, KO, CVS, JPM pay a dividend while NAKA, TDOC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.